Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. (October 2020) - Gounder, M.M.; Bauer, T.M.; Schwartz, G.K.; LoRusso, P.; Kumar, P.; Kato, K.; Tao, B.; Hong, Y.; Patel, P.; Hong, D.